Renewed interest in neutrophil transfusions has emerged with the development and clinical use of granulocyte colony-stimulating factor (G-CSF). G-CSF not only increases neutrophil (polymorphonuclear leukocyte, PMNL) production but also modulates various physiological properties of PMNL. The effects of G-CSF on PMNL-mediated fungicidal activity were evaluated by administration of G-CSF (300 mg/day subcutaneously) to 5 healthy volunteers for 6 days. G-CSF significantly enhanced PMNL-mediated damage of Candida albicans pseudohyphae by 33% ( ) on day 2 and by 44% ( ) on day 6 at a 10:1 effector:target P ϭ .007 P ϭ .04 ratio. In contrast, the ability of PMNL to induce damage of hyphae from either Fusarium solani or Aspergillus fumigatus did not significantly change during the study period. These data demonstrate that G-CSF administered in vivo modulates PMNL-mediated fungicidal activity against the pseudohyphal form of C. albicans, thereby suggesting potential utility of G-CSF as a biologic response-modifying therapy in some opportunistic fungal infections.
PMNLs, including respiratory (oxidative) burst activity, microbicidal activity, degranulation, and expression of FcgRI (CD 64) [6] .
We reported previously that in vivo administration of G-CSF to healthy volunteers effectively primed PMNL for sustained production of reactive oxygen species, as measured by luminol-enhanced chemiluminescence, in response to aqueous extracts of A. fumigatus, Rhizopus arrhizus, and C. albicans [7] . Furthermore, G-CSF significantly enhanced PMNL-mediated killing of A. fumigatus and R. arrhizus conidia [7] . Administration of G-CSF to individuals infected with human immunodeficiency virus-type 1 (HIV-1) has also been reported to enhance PMNL-mediated fungicidal activity against C. albicans and Cryptococcus neoformans [8] . In vitro, G-CSF has been shown to prime normal and defective PMNLs for increased antifungal activity against A. fumigatus hyphae [9, 10] . However, in vitro experiments evaluating the ability of G-CSF to prime PMNLs for enhanced fungicidal activity against C. albicans blastoconidia and pseudohyphae have yielded conflicting results [7, 11, 12] .
Lately, a renewed interest in granulocyte transfusion therapy has evolved, based largely on the ability to obtain high yields of PMNLs by leukapheresis after stimulation of donors with G-CSF [13, 14] . Although the effects of G-CSF on PMNLmediated fungicidal activity have been studied in vitro, much less attention has been focused on the effect of G-CSF administered in vivo on PMNL-mediated antifungal activity. Because hyphae (or pseudohyphae) are the predominant stage of opportunistic fungi in host tissues during invasive infection, we administered G-CSF (300 mg/day subcutaneously for 6 days) to healthy volunteers, to evaluate its effect on PMNL-mediated antifungal activity against hyphal and pseudohyphal forms of 
Materials and Methods
Organisms. The isolates of A. fumigatus, F. solani, and C. albicans used in this study are well-characterized clinical isolates obtained from patients with invasive fungal infections at the Fred Hutchinson Cancer Research Center (Seattle). Stock fungal isolates were maintained by standard microbiologic methods. Conidia (A. fumigatus and F. solani) and blastoconidia (C. albicans) were suspended in RPMI 1640 without phenol red, containing 10 mM HE-PES, pH 7.4 (RPMI/HEPES; Life Technologies, Gibco BRL, Grand Island, NY). Conidia and blastoconidia were counted in a hemocytometer and adjusted to a final concentration of 5 1 ϫ 10 conidia/mL and blastoconidia/mL. Aliquots of 100 mL were 4 1 ϫ 10 dispensed into 96-well flat-bottomed plates (Costar, Cambridge, MA), and incubated for 16 h to form hyphae and pseudohyphae (A. fumigatus at 37ЊC; F. solani and C. albicans, 25ЊC). More than 95% of conidia and blastoconidia germinated (hyphal length, 160-200 mm; pseudohyphal length, 80-100 mm).
Reagents. Recombinant human G-CSF ( U/mg) was 8 1 ϫ 10 provided by Amgen (Thousand Oaks, CA). A 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide solution (XTT; Sigma, St. Louis) was prepared fresh daily in Dulbecco's PBS (Life Technologies) at 0.5 mg/mL with heating at 55ЊC for 30 min, 2,3-dimethoxy-5-methyl-1,4-benzoquinone (coenzyme Q; Sigma) was added at 50 mg/mL, and the solution was passed through a 0.22-mm filter.
Study design. Five healthy human volunteers (age, 25-49 years; weight, 67-85 kg) received 300 mg of G-CSF subcutaneously each morning for 5 consecutive days. All volunteers were nonsmokers, had normal physical examination findings, were receiving no concomitant medications, and had not experienced an acute illness during the 6 weeks preceding the study. All volunteers underwent screening consisting of physical examination and complete blood count.
PMNL purification. Venous blood was collected from healthy human volunteers on day 0 before G-CSF administration, on day 2 (approximately 18 h after the second dose of G-CSF), and on day 6 (approximately 18 h after the sixth dose of G-CSF), with 0.2% K 2 EDTA used as anticoagulant. PMNLs were isolated by sequential centrifugation on Histopaque-1077 (Sigma), sedimentation in 3% Dextran (Sigma) in 0.9% sodium chloride, and hypotonic lysis of remaining erythrocytes. After separation, PMNLs were suspended in RPMI/HEPES. PMNL purity was 198%, and cell viability was 198% as determined by trypan blue exclusion.
Hyphal damage assay. PMNL-mediated hyphal damage was measured by modification of an XTT-based assay system described by Meshulam et al. [15] . PMNLs suspended in RPMI/HEPES plus 20% autologous serum were dispensed in 100-mL aliquots to achieve effector:target (E:T) ratios of 10:1 and 1:1. Each condition was performed in quadruplicate. PMNLs were gently sedimented to the bottom of the well by centrifugation at 400 g for 3 min, and then the plates were gently rocked at 37ЊC for 2 h. Blank wells, containing only RPMI/HEPES plus serum, and control wells with only hyphae or cells were also prepared and subjected to the same experimental conditions as the test wells. After incubation, 100 mL of fluid was aspirated and PMNLs lysed by addition of 100 mL of ice-cold distilled water, followed by centrifugation at 2000 g for 7 min at 1ЊC. One hundred microliters of fluid was then aspirated, and the procedure was repeated once. Microscopic examination confirmed that cells were completely lysed by this process.
We assessed fungal viability by adding 100 mL of XTT solution to each well and rocking the plates for 1 h at 37ЊC. Absorbance of each well was determined at 450 nm by use of a microplate spectrophotometer (Automated Microplate Reader, Model EL309, Bio-Tek Instruments, Inc., Winooski, VT). 
Results
The absolute neutrophil count (ANC) in the venous blood of the 5 healthy volunteers increased from a mean baseline value of 3402/mL (range, 2600-5248/mL) before administration of G-CSF to a mean value of 21,275/mL (range, 14,025-34,400/mL) after the second dose of G-CSF, and to a mean value of 24,450/ mL (range, 17,085-36,720/mL) after the sixth consecutive daily dose of G-CSF (table 1). The increase in ANC observed after G-CSF administration was predominantly due to enhancement in the population of mature neutrophils. Bands were the least mature cells of the neutrophil lineage observed in the peripheral ). P ! .05 blood smear. G-CSF treatment was well tolerated by the volunteers, with only 1 volunteer reporting mild low back pain on days 5 and 6 of the study period.
The effect of in vivo administration of G-CSF on PMNLmediated fungicidal activity against opportunistic fungi was evaluated by hyphal/pseudohyphal damage assay using an XTT assay ( figure 1) . In vivo administration of G-CSF significantly enhanced PMNL-mediated fungicidal activity against C. albicans pseudohyphae. At baseline (day 0) prior to administration of G-CSF, ( ) and pseu-57% ‫ע‬ 10% mean ‫ע‬ SE 47% ‫ע‬ 11% dohyphal damage was observed at E:T ratios of 10:1 and 1:1, respectively. After the second dose of G-CSF (day 2), mean hyphal damage increased to at a 10:1 E:T ratio 76% ‫ע‬ 10% (
) and to at a 1:1 E:T ratio. Enhanced P ϭ .007 68% ‫ע‬ 13% PMNL-mediated activity against C. albicans persisted throughout the duration of G-CSF administration. After the sixth dose of G-CSF (day 6), mean hyphal damage increased to 82% ‫ע‬ at a 10:1 E:T ratio ( ) and to at a 1:1 9% P ϭ .04 67% ‫ע‬ 17% E:T ratio.
In contrast, fungicidal activity against F. solani hyphae was not significantly affected by G-CSF. At baseline, PMNL-mediated hyphal damage was at a 10:1 E:T ratio and 31% ‫ע‬ 4% at a 1:1 E:T ratio. After the second dose of G-CSF, 18% ‫ע‬ 5% hyphal damage was observed at a 10:1 E:T ratio 37% ‫ע‬ 9% and damage at a 1:1 E:T ratio. After the sixth dose 24% ‫ע‬ 8% of G-CSF, PMNL-mediated hyphal damage remained unchanged, with damage observed at a 10:1 E:T ratio and 36% ‫ע‬ 9% at a 1:1 E:T ratio. Likewise, PMNL-mediated fun-16% ‫ע‬ 5% gicidal activity against A. fumigatus hyphae was not significantly affected by in vivo administration of G-CSF. On day 0, the hyphal damage was and at 10:1 and 43% ‫ע‬ 5% 34% ‫ע‬ 3% 1:1 E:T ratios, respectively. After the second dose of G-CSF, the mean hyphal damage was at a 10:1 E:T ratio 43% ‫ע‬ 1% and at a 1:1 E:T ratio. After the sixth dose of G-35% ‫ע‬ 5% CSF, the mean hyphal damage was at a 10:1 E:T 40% ‫ע‬ 5% ratio and at a 1:1 E:T ratio. 31% ‫ע‬ 6%
Discussion
We reported elsewhere that in vivo administration of G-CSF failed to augment PMNL-mediated killing of C. albicans blastoconidia subsequently measured in vivo. In contrast, the present study demonstrates that in vivo administration of G-CSF to healthy volunteers effectively enhances PMNL-mediated antifungal activity against C. albicans pseudohyphae, which predominate at sites of invasive tissue infection. After the second dose of G-CSF (day 2), the degree of PMNL-mediated fungal damage was significantly enhanced by 33% above the baseline ( ) at a 10:1 E:T ratio. After the sixth dose of G-CSF P ϭ .007 (day 6), PMNL-mediated pseudohyphal damage was further enhanced to 44% ( ) above the baseline antifungal ac-P ϭ .04 tivity. Although G-CSF had a beneficial effect on PMNL-mediated fungicidal activity against C. albicans at the 2 different E:T ratios studied, the difference in pseudohyphal damage was significant only at the 10:1 E:T ratio, suggesting that the number of PMNLs at the site of infection plays a pivotal role in the resolution of invasive candidiasis.
Although the administration of G-CSF in vivo failed to significantly enhance PMNL-mediated hyphal damage of A. fumigatus and F. solani, PMNLs retained fungicidal activity against these organisms for the duration of G-CSF treatment. PMNL-mediated antifungal activity against A. fumigatus hyphae was essentially unchanged after the second and the sixth doses of G-CSF. On the other hand, PMNL-mediated hyphal damage of F. solani was slightly increased at a 10:1 E:T ratio to 20% above baseline after the second dose of G-CSF and to 16% above baseline after the sixth dose of G-CSF. However, these results do not exclude the possibility that G-CSF in vivo could increase the fungicidal activity of defective PMNLs, as reported in HIV-1-infected patients [8, 10] .
With the increasing use of dose-intensive chemotherapy for solid tumors and myeloid malignancies, as well as the increasing number of marrow transplantations being done, a growing number of neutropenic patients develop serious and often fatal invasive fungal infections [1, 3] . The use of G-CSF in healthy donors not only allows the collection of adequate numbers of PMNLs for transfusion but also preserves and, in some cases, enhances PMNL-mediated activity against opportunistic fungal hyphae or pseudohyphae that predominate at sites of invasive tissue infection. However, only controlled clinical trials can establish the proper role of G-CSF as an adjunctive immunomodulatory agent for the treatment of patients with invasive infections by opportunistic fungal pathogens.
